SG10201402628VA - Specific Diarylhydantoin And Diarylthiohydantoin Compounds - Google Patents

Specific Diarylhydantoin And Diarylthiohydantoin Compounds

Info

Publication number
SG10201402628VA
SG10201402628VA SG10201402628VA SG10201402628VA SG10201402628VA SG 10201402628V A SG10201402628V A SG 10201402628VA SG 10201402628V A SG10201402628V A SG 10201402628VA SG 10201402628V A SG10201402628V A SG 10201402628VA SG 10201402628V A SG10201402628V A SG 10201402628VA
Authority
SG
Singapore
Prior art keywords
diarylhydantoin
specific
diarylthiohydantoin compounds
diarylthiohydantoin
compounds
Prior art date
Application number
SG10201402628VA
Inventor
Rajendra Parasmal Jain
Jacqueline A Gibbons
Original Assignee
Medivation Prostate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42665887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201402628V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Inc filed Critical Medivation Prostate Therapeutics Inc
Publication of SG10201402628VA publication Critical patent/SG10201402628VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201402628VA 2009-02-24 2010-02-24 Specific Diarylhydantoin And Diarylthiohydantoin Compounds SG10201402628VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15511909P 2009-02-24 2009-02-24
US15639809P 2009-02-27 2009-02-27

Publications (1)

Publication Number Publication Date
SG10201402628VA true SG10201402628VA (en) 2014-10-30

Family

ID=42665887

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2011061066A SG173837A1 (en) 2009-02-24 2010-02-24 Specific diarylhydantoin and diarylthiohydantoin compounds
SG10201402628VA SG10201402628VA (en) 2009-02-24 2010-02-24 Specific Diarylhydantoin And Diarylthiohydantoin Compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2011061066A SG173837A1 (en) 2009-02-24 2010-02-24 Specific diarylhydantoin and diarylthiohydantoin compounds

Country Status (16)

Country Link
US (2) US8524755B2 (en)
EP (1) EP2400847B1 (en)
JP (2) JP2012518661A (en)
KR (1) KR20110130439A (en)
CN (1) CN102421291A (en)
AU (1) AU2010218052A1 (en)
BR (1) BRPI1007990A2 (en)
CA (1) CA2753425A1 (en)
ES (1) ES2535466T3 (en)
IL (1) IL214800A0 (en)
MX (1) MX2011008858A (en)
NZ (1) NZ594741A (en)
RU (1) RU2548918C2 (en)
SG (2) SG173837A1 (en)
WO (1) WO2010099238A1 (en)
ZA (2) ZA201106200B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
SG10201408699TA (en) * 2006-03-29 2015-02-27 Univ California Diarylthiohydantoin compounds
EP2620432A3 (en) 2007-10-26 2013-12-18 The Regents Of the University of California Diarylhydantoin compounds
US8710086B2 (en) * 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
AU2016208310B2 (en) * 2010-02-16 2017-10-05 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
AU2014271290C1 (en) * 2010-02-16 2016-10-27 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP3124481B1 (en) * 2010-02-16 2018-03-28 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
DK3329775T3 (en) * 2010-02-24 2021-07-26 Medivation Prostate Therapeutics Llc Methods for synthesizing diarylthiohydantoin and diarylhydantoin compounds
US20140088178A1 (en) * 2011-03-14 2014-03-27 The University Of British Columbia Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer
MX359664B (en) * 2011-07-29 2018-10-05 Univ Colorado Regents Treatment of breast cancer.
WO2013067151A1 (en) * 2011-11-02 2013-05-10 Medivation Prostate Therapeutics, Inc. Treatment methods using diarylthiohydantoin derivatives
WO2013067131A1 (en) * 2011-11-02 2013-05-10 Medivation Technologies, Inc. Treatment methods
EP2664325A1 (en) * 2012-05-16 2013-11-20 PregLem S.A. Methods for preventing or treating androgen mediated diseases
SG10201912719TA (en) 2012-09-26 2020-02-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (en) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
WO2014167428A2 (en) * 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
CN104803919A (en) * 2014-01-26 2015-07-29 上海医药工业研究院 Preparation method of enzalutamide intermediate F
CN104844520B (en) * 2014-02-13 2017-09-05 成都伊诺达博医药科技有限公司 A kind of method for synthesizing the miscellaneous Shandong amine of grace
CN104844521B (en) * 2014-02-13 2017-08-15 成都伊诺达博医药科技有限公司 The synthetic method of the miscellaneous Shandong amine of antiprostate cancer grace
RU2557235C1 (en) * 2014-07-08 2015-07-20 Александр Васильевич Иващенко Substituted 2-thioxo-imidazolidin-4-one, and spiroanalogues thereof, anticancer active ingredient, pharmaceutical composition, medicinal product, method of treating prostate cancer
US10131636B2 (en) * 2014-10-01 2018-11-20 Laurus Labs Limited Process for the preparation of Enzalutamide
EP3230471B1 (en) 2014-12-12 2019-08-28 Medivation Prostate Therapeutics LLC Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
TWI613194B (en) 2015-06-10 2018-02-01 台灣神隆股份有限公司 A novel process for preparing enzalutamide
TWI726969B (en) 2016-01-11 2021-05-11 比利時商健生藥品公司 Substituted thiohydantoin derivatives as androgen receptor antagonists
WO2018007624A1 (en) * 2016-07-08 2018-01-11 Actavis Group Ptc Ehf Enzalutamide derivatives for the treatment of prostate and breast cancer
CN107954936B (en) * 2016-10-17 2021-03-19 海创药业股份有限公司 Method for preparing deuterated imidazoldione compound
CN107501237B (en) * 2017-08-17 2022-03-22 上海西浦医药科技有限公司 Synthetic method of Apalutamide
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
JP2022509917A (en) 2018-11-05 2022-01-25 ファイザー・インク Combinations for treating cancer
JP2023537595A (en) 2020-08-13 2023-09-04 ファイザー・インク combination therapy
PE20240248A1 (en) 2020-12-11 2024-02-19 Ildong Pharmaceutical Co Ltd NEW COMPOUNDS AS A DUAL INHIBITOR OF THE ANDROGEN RECEPTOR AND PHOSPHODIESTERASE
CA3214316A1 (en) 2021-03-24 2022-09-29 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
KR20240060809A (en) * 2021-09-08 2024-05-08 어치브 라이프 사이언시즈, 인크. Analytical Methods for Assessing Cytisine Purity
WO2024127140A1 (en) 2022-12-17 2024-06-20 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5136332B1 (en) 1970-12-09 1976-10-07
FR2715402B1 (en) * 1994-01-05 1996-10-04 Roussel Uclaf New phenylimidazolines optionally substituted, their process and preparation intermediates, their use as medicaments and the pharmaceutical compositions containing them.
GB0200283D0 (en) * 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
US7173044B2 (en) * 2004-02-19 2007-02-06 Solvay Pharmaceuticals B.V. Imidazoline derivatives having CB1-antagonistic activity
US20060030871A1 (en) 2004-08-05 2006-02-09 Matthew Hain Vascular tunneler
JP2008511114A (en) * 2004-08-26 2008-04-10 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Lamp with reflective coating
WO2006028226A1 (en) * 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Novel imidazolidine derivative and use thereof
ATE387259T1 (en) * 2005-05-13 2008-03-15 Protectron Nanocomposites Pte IMPROVED COLLOIDAL GEL FOR PROTECTIVE TEXTILE, IMPROVED PROTECTIVE TEXTILE AND PRODUCTION METHOD THEREOF
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR101332924B1 (en) * 2005-05-13 2013-11-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 Diarylhydantoin compounds
SG10201408699TA (en) 2006-03-29 2015-02-27 Univ California Diarylthiohydantoin compounds
EP2620432A3 (en) 2007-10-26 2013-12-18 The Regents Of the University of California Diarylhydantoin compounds

Also Published As

Publication number Publication date
EP2400847A4 (en) 2012-08-08
JP2015028085A (en) 2015-02-12
SG173837A1 (en) 2011-09-29
MX2011008858A (en) 2012-01-27
US20130331421A1 (en) 2013-12-12
ZA201303499B (en) 2015-03-25
ZA201106200B (en) 2013-07-31
BRPI1007990A2 (en) 2015-09-01
AU2010218052A1 (en) 2011-09-08
RU2011139107A (en) 2013-04-10
NZ594741A (en) 2014-03-28
WO2010099238A1 (en) 2010-09-02
RU2548918C2 (en) 2015-04-20
CA2753425A1 (en) 2010-09-02
CN102421291A (en) 2012-04-18
JP2012518661A (en) 2012-08-16
EP2400847A1 (en) 2012-01-04
IL214800A0 (en) 2011-11-30
EP2400847B1 (en) 2014-12-17
US9023879B2 (en) 2015-05-05
ES2535466T3 (en) 2015-05-11
US20120035231A1 (en) 2012-02-09
KR20110130439A (en) 2011-12-05
US8524755B2 (en) 2013-09-03

Similar Documents

Publication Publication Date Title
ZA201303499B (en) Specific diarylhydantoin and diarylthiohydantion compounds
LT3222617T (en) Psma-targeting compounds and uses thereof
DK3023438T3 (en) Anti-gitr-antistoffer
DK2457337T3 (en) Specialtilpasset impuls-burst
GB0919432D0 (en) Use
EP2462514A4 (en) Greenbooks
EP2515891A4 (en) 3-keto-n-propargyl-1-aminoindan
EP2519921A4 (en) Call-tracking
DK2464943T3 (en) Systemintegration
GB0922505D0 (en) Use
GB0902173D0 (en) Compounds and their use
GB0909768D0 (en) Novel compounds and uses thereof
GB0922510D0 (en) Compound and use
EP2470022A4 (en) Compounds and methods
GB0903348D0 (en) Compounds and methods relating thereto
GB0905525D0 (en) Compounds and uses
EP2510125A4 (en) Hyperprimers
GB0917304D0 (en) Use
PL387177A1 (en) Enaminocarbonylic compounds and their application
GB0905231D0 (en) Compounds and their use
AU4926P (en) Bonscalib Scaevola aemula
AU4925P (en) Bonscawi Scaevola aemula
AU4240P (en) Tuckerbox xTriticosecale
AU4924P (en) Bonscablue Scaevola aemula
GB0908087D0 (en) Novel compounds and uses thereof